Four-Gene Signature Predicts Prostate Cancer Recurrence and Flags SPAG5 as Drug Target
A four-gene transcriptomic signature stratifies prostate cancer patients by biochemical recurrence risk and identifies SPAG5 as a targetable oncogene.
A four-gene transcriptomic signature stratifies prostate cancer patients by biochemical recurrence risk and identifies SPAG5 as a targetable oncogene.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine